p66Shc deletion confers apoptotic resistance to loss of EGFR-ERK signalling in neural stem cells

Submitted by Anonymous on

Growth factor signalling, through epidermal growth factor (EGF) and its receptor (EGFR), governs neural stem cell (NSC) proliferation, differentiation, and survival. The Src Homology and Collagen (SHC1) adaptor protein mediates EGFR survival-signalling in NSCs via its two shorter isoforms. However,...

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC

Submitted by Anonymous on

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC The combination of savolitinib and osimertinib significantly improved PFS, ORR, and DOR compared to chemotherapy in EGFR-mutated, MET-amplified NSCLC. The SACHI trial showed consistent PFS benefits across subgroups, including patients...

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Submitted by Anonymous on

- Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy - - The only all-oral combination treatment option for these patients - - Consistent benefit regardless...

Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma

Submitted by Anonymous on

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma...

Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Submitted by Anonymous on

Open AccessReview Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer by Panagiotis Agisilaos AngelopoulosPanagiotis Agisilaos Angelopoulos SciProfiles Scilit Preprints.org Google Scholar 1, Antonio PassaroAntonio Passaro SciProfiles Scilit Preprints.org Google Scholar 2,*, Ilaria AttiliIlaria Attili SciProfiles Scilit...

Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro

Submitted by Anonymous on

Open AccessCommunication Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro by Hanshuang ShaoHanshuang Shao SciProfiles Scilit Preprints.org Google Scholar 1 and Alan WellsAlan Wells SciProfiles Scilit Preprints.org Google Scholar 1,2,* 1 Department of Pathology, University of...

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study | AVBP Sto

Submitted by Anonymous on

ArriVent BioPharma (AVBP, Financial) reports positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC. The trial shows a 16.0-month median progression-free survival and a 68.2% overall response rate at the 240mg dose. The Phase 3 ALPACCA trial,...

Subscribe to Newsfeed